Feb 28 (Reuters) - Next Science Ltd (NXS) :
- REAFFIRM FY24 GUIDANCE FOR REVENUE OF US$36M-40M
- EXPECTS TO BE EBITDA AND CASHFLOW POSITIVE IN 2H FY24
- Forums
- ASX - By Stock
- NXS
- News: NXS Next Science Says Reaffirm FY24 Guidance For Revenue Of $36 Mln-$40 Mln
News: NXS Next Science Says Reaffirm FY24 Guidance For Revenue Of $36 Mln-$40 Mln
Featured News
Add NXS (ASX) to my watchlist
|
|||||
Last
26.5¢ |
Change
-0.010(3.64%) |
Mkt cap ! $77.29M |
Open | High | Low | Value | Volume |
27.0¢ | 27.0¢ | 25.5¢ | $41.52K | 156.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 20000 | 26.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
26.5¢ | 2488 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3160 | 0.260 |
3 | 42039 | 0.250 |
3 | 87613 | 0.240 |
3 | 9939 | 0.230 |
5 | 132255 | 0.200 |
Price($) | Vol. | No. |
---|---|---|
0.265 | 2488 | 1 |
0.275 | 17850 | 2 |
0.280 | 13571 | 2 |
0.285 | 75660 | 1 |
0.290 | 18466 | 3 |
Last trade - 16.10pm 18/06/2024 (20 minute delay) ? |
Featured News
NXS (ASX) Chart |
The Watchlist
CC9
CHARIOT CORPORATION LTD
Shanthar Pathmanathan, MD
Shanthar Pathmanathan
MD
Previous Video
Next Video
SPONSORED BY The Market Online